GSK’s Zejula reduces risk of progression and death in mesothelioma study
GSK’s Zejula (niraparib) has reduced the risk of death or progression by 27% in patients with mesothelioma in an investigator-led…
Oncology
-
-
AstraZeneca’s Truqap fails in another Phase III trial
AstraZeneca has discontinued a Phase III trial of Truqap (capivasertib) after a review concluded that the study was unlikely to…
-
EC conditionally approves Regeneron’s Lynozyfic for multiple myeloma
The European Commission (EC) has granted conditional marketing approval to Regeneron Pharmaceuticals’ bispecific antibody Lynozyfic (linvoseltamab) for adults with relapsed…
-
Merck KGaA strikes $3.9bn deal for SpringWorks
Merck KGaA (Merck) has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire…
-
China approves InnoCare Pharma’s BTK inhibitor for lymphoma
China’s National Medical Products Administration (NMPA) has approved InnoCare Pharma’s Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib for use as a…
-
Merck KGaA nears $3.5bn deal for SpringWorks
Merck KGaA is edging closer to the SpringWorks deal, which was first rumoured in February, confirming late-stage negotiations at an…
-
FDA approves Akeso’s monoclonal antibody for nasopharyngeal carcinoma
The US Food and Drug Administration (FDA) has granted approval to Akeso's differentiated programmed cell death protein 1 (PD-1) monoclonal…
-
Veraxa to go public in $1.6bn SPAC deal with Voyager
Swiss oncology firm Veraxa Biotech is set to go public in the US through a merger with Voyager Acquisition Corp,…
-
Boehringer to expand oncology presence with $572m Tessellate Bio deal
Boehringer Ingelheim has signed a €500m ($572m) agreement with UK-based biotech Tessellate Bio to co-develop targeted cancer therapies for tumours…
-
UK’s MHRA authorises GSK’s Blenrep for multiple myeloma treatment
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorised GSK’s Blenrep for treating multiple myeloma (MM). This authorisation…
